Forum Topic News
  • Conversation: CTI slumps as Servier-partnered lymphoma drug fails

    • July 10, 2018 12:56 PM BST
      • Post(s)

      CTI slumps as Servier-partnered lymphoma drug fails

      CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure.
      The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a monotherapy for hard-to-treat NHL – with Roche’s MabThera (rituximab) and compared it to MabThera plus gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint.
      Shares in CTI were suspended as the news broke but slumped after trading resumed as investors came to terms with both a threat to the drug’s EU approval, and little chance of a route towards US approval.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel